C-MYC is overexpressed in up to 15 % of DLBCL-NOS and in up to 58 % of DLBCL, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (DLBCL/BL) as a result of the t(8,14) translocation (5–14 %), gain/amplification (8q24) (21–38 %) or other, epigenetic mechanisms (28–41 %) [136, 137]. This evidence concerns the gene MYC and Burkitt lymphoma.